JPWO2020132465A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020132465A5 JPWO2020132465A5 JP2021535554A JP2021535554A JPWO2020132465A5 JP WO2020132465 A5 JPWO2020132465 A5 JP WO2020132465A5 JP 2021535554 A JP2021535554 A JP 2021535554A JP 2021535554 A JP2021535554 A JP 2021535554A JP WO2020132465 A5 JPWO2020132465 A5 JP WO2020132465A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- therapeutic composition
- composition
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025183107A JP2026021440A (ja) | 2018-12-20 | 2025-10-30 | がん治療のための治療用ペプチドに関する方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782690P | 2018-12-20 | 2018-12-20 | |
| US62/782,690 | 2018-12-20 | ||
| PCT/US2019/067890 WO2020132465A1 (en) | 2018-12-20 | 2019-12-20 | Methods and compositions related to therapeutic peptides for cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025183107A Division JP2026021440A (ja) | 2018-12-20 | 2025-10-30 | がん治療のための治療用ペプチドに関する方法および組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022514354A JP2022514354A (ja) | 2022-02-10 |
| JP2022514354A5 JP2022514354A5 (https=) | 2022-12-06 |
| JPWO2020132465A5 true JPWO2020132465A5 (https=) | 2022-12-06 |
| JP7773195B2 JP7773195B2 (ja) | 2025-11-19 |
Family
ID=71101609
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535554A Active JP7773195B2 (ja) | 2018-12-20 | 2019-12-20 | がん治療のための治療用ペプチドに関する方法および組成物 |
| JP2025183107A Pending JP2026021440A (ja) | 2018-12-20 | 2025-10-30 | がん治療のための治療用ペプチドに関する方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025183107A Pending JP2026021440A (ja) | 2018-12-20 | 2025-10-30 | がん治療のための治療用ペプチドに関する方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3897669A4 (https=) |
| JP (2) | JP7773195B2 (https=) |
| CN (2) | CN113677351B (https=) |
| AU (1) | AU2019403393B2 (https=) |
| CA (1) | CA3123853A1 (https=) |
| WO (1) | WO2020132465A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4199947A4 (en) | 2020-08-18 | 2024-10-16 | Onchilles Pharma, Inc. | Modified porcine pancreatic elastase proteins |
| WO2022056488A1 (en) * | 2020-09-14 | 2022-03-17 | Genprex, Inc. | Nonviral vectors for increasing fas expression in cancer cells and methods of use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP1178817A2 (en) * | 1999-05-14 | 2002-02-13 | Arbor Vita Corporation | Molecular interactions in haematopoietic cells |
| US7608413B1 (en) * | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
| WO2008067305A2 (en) * | 2006-11-28 | 2008-06-05 | Giic Research Development Corporation | Polypeptides comprising intracytoplasmic death domain and nkg2d ligand domain |
| ES2523992T3 (es) * | 2006-12-28 | 2014-12-03 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | La neutralización de la actividad de CD95 bloquea la invasión de células de glioblastoma in vivo |
| JP6153526B2 (ja) * | 2011-09-06 | 2017-06-28 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | ポリペプチドワクチン |
| GB201121070D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
| BR112015008612A2 (pt) * | 2012-10-17 | 2017-09-26 | Vascular Biogenics Ltd | métodos de tratamento utilizando adenovirus |
| WO2014118643A2 (en) * | 2013-02-04 | 2014-08-07 | Vascular Biogenics Ltd. | Methods of inducing responsiveness to anti-angiogenic agent |
| GB201506223D0 (en) * | 2015-04-13 | 2015-05-27 | Ucl Business Plc | Chimeric protein |
| WO2018073394A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Cell death inducing chimeric antigen receptors |
| EP4292606B1 (en) * | 2017-06-15 | 2025-11-12 | The University of Chicago | Compositions for treating cancer |
| WO2019051001A1 (en) * | 2017-09-06 | 2019-03-14 | California Institute Of Technology | SIGNALING AND BIFUNCTIONAL RECEPTORS HAVING ANTIGENS (SABR) |
-
2019
- 2019-12-20 AU AU2019403393A patent/AU2019403393B2/en active Active
- 2019-12-20 JP JP2021535554A patent/JP7773195B2/ja active Active
- 2019-12-20 CN CN201980092976.7A patent/CN113677351B/zh active Active
- 2019-12-20 CN CN202411342304.6A patent/CN119015448A/zh active Pending
- 2019-12-20 CA CA3123853A patent/CA3123853A1/en active Pending
- 2019-12-20 EP EP19899959.1A patent/EP3897669A4/en active Pending
- 2019-12-20 WO PCT/US2019/067890 patent/WO2020132465A1/en not_active Ceased
-
2025
- 2025-10-30 JP JP2025183107A patent/JP2026021440A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2909664T3 (es) | Composición farmacéutica que comprende arginina desiminasa de unión a albúmina para el tratamiento dirigido del cáncer | |
| JP2018510881A5 (https=) | ||
| JP2020524141A5 (https=) | ||
| HRP20151172T1 (hr) | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka | |
| Jiang et al. | Targeted delivery of CXCR4-siRNA by scFv for HER2+ breast cancer therapy | |
| RU2012137503A (ru) | Лекарственный препарат для лечения и/или профилактики рака | |
| WO2008020596A3 (en) | Treating or preventing cancers over-expressing reg4 or kiaa0101 | |
| JP2015519346A5 (https=) | ||
| RU2007136026A (ru) | Варианты ил-21 | |
| JP2019507582A5 (https=) | ||
| JP6876618B2 (ja) | 治療目的のための抗体−ウレアーゼコンジュゲート | |
| JP2010513405A (ja) | 二量体プロラクチンレセプターリガンド | |
| US10532109B2 (en) | Peptide-DNA chimeras for treatment of HER overexpressing cancers | |
| JP2015516370A5 (https=) | ||
| JP2018506287A5 (https=) | ||
| US10806715B2 (en) | Gold nanoparticle based formulation for use in cancer therapy | |
| JP2017503862A (ja) | インスリン様成長因子−１および上皮増殖因子を含む融合タンパク質およびそのバリアントならびにその使用 | |
| WO2019204563A9 (en) | Cyclic peptide for treating cancer | |
| EP4622996A1 (en) | Control of nanocage self-assembly | |
| JPWO2020132465A5 (https=) | ||
| AU2012281131B2 (en) | Novel zinc finger-like peptide compositions as potent agents in cancer prevention and treatment | |
| CN115804853A (zh) | 包含rna分子的组合物及其在制备瘤内注射剂中的用途 | |
| CN105985447B (zh) | 一种白蛋白结合型肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 | |
| Ma et al. | SDF-1/54-DCN: a novel recombinant chimera with dual inhibitory effects on proliferation and chemotaxis of tumor cells | |
| CN104470533A (zh) | 使用血管生成素或血管生成素激动剂治疗癌症的方法 |